Cargando…

L-Type Amino Acid Transporter 1-Utilizing Prodrugs of Ketoprofen Can Efficiently Reduce Brain Prostaglandin Levels

In order to efficiently combat neuroinflammation, it is essential to deliver the anti-inflammatory drugs to their target sites in the brain. Pro-drugs utilizing the L-type amino acid transporter 1 (LAT1) can be transported across the blood-brain barrier (BBB) and the cellular barriers of the brain’s...

Descripción completa

Detalles Bibliográficos
Autores principales: Montaser, Ahmed, Lehtonen, Marko, Gynther, Mikko, Huttunen, Kristiina M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238114/
https://www.ncbi.nlm.nih.gov/pubmed/32290494
http://dx.doi.org/10.3390/pharmaceutics12040344
_version_ 1783536469463269376
author Montaser, Ahmed
Lehtonen, Marko
Gynther, Mikko
Huttunen, Kristiina M.
author_facet Montaser, Ahmed
Lehtonen, Marko
Gynther, Mikko
Huttunen, Kristiina M.
author_sort Montaser, Ahmed
collection PubMed
description In order to efficiently combat neuroinflammation, it is essential to deliver the anti-inflammatory drugs to their target sites in the brain. Pro-drugs utilizing the L-type amino acid transporter 1 (LAT1) can be transported across the blood-brain barrier (BBB) and the cellular barriers of the brain’s parenchymal cells. In this study, we evaluated, for the first time, the efficacy of LAT1-utilizing prodrugs of ketoprofen (KPF) on cyclooxygenase (COX) enzymes in vitro and prostaglandin E2 production in vivo by using an enzymatic assay and liquid chromatography- tandem mass spectrometry method, respectively. Aliphatic amino acid-conjugated pro-drugs inhibited the peroxidase activity of COX in vitro in their intact form (85% inhibition, IC50 ≈ 1.1 µM and 79%, IC50 ≈ 2.3 µM), which was comparable to KPF (90%, IC50 ≈ 0.9). Thus, these compounds acted more as KPF derivatives rather than pro-drugs. In turn, aromatic amino acid-conjugated pro-drugs behaved differently. The ester pro-drug inhibited the COX peroxidase activity in vitro (90%, IC50 ≈ 0.6 µM) due to its bioconversion to KPF, whereas the amide pro-drug was inactive toward COX enzymes in vitro. However, the amide pro-drug released KPF in the mouse brain in sufficient and effective amounts measured as reduced PGE2 levels.
format Online
Article
Text
id pubmed-7238114
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72381142020-05-28 L-Type Amino Acid Transporter 1-Utilizing Prodrugs of Ketoprofen Can Efficiently Reduce Brain Prostaglandin Levels Montaser, Ahmed Lehtonen, Marko Gynther, Mikko Huttunen, Kristiina M. Pharmaceutics Article In order to efficiently combat neuroinflammation, it is essential to deliver the anti-inflammatory drugs to their target sites in the brain. Pro-drugs utilizing the L-type amino acid transporter 1 (LAT1) can be transported across the blood-brain barrier (BBB) and the cellular barriers of the brain’s parenchymal cells. In this study, we evaluated, for the first time, the efficacy of LAT1-utilizing prodrugs of ketoprofen (KPF) on cyclooxygenase (COX) enzymes in vitro and prostaglandin E2 production in vivo by using an enzymatic assay and liquid chromatography- tandem mass spectrometry method, respectively. Aliphatic amino acid-conjugated pro-drugs inhibited the peroxidase activity of COX in vitro in their intact form (85% inhibition, IC50 ≈ 1.1 µM and 79%, IC50 ≈ 2.3 µM), which was comparable to KPF (90%, IC50 ≈ 0.9). Thus, these compounds acted more as KPF derivatives rather than pro-drugs. In turn, aromatic amino acid-conjugated pro-drugs behaved differently. The ester pro-drug inhibited the COX peroxidase activity in vitro (90%, IC50 ≈ 0.6 µM) due to its bioconversion to KPF, whereas the amide pro-drug was inactive toward COX enzymes in vitro. However, the amide pro-drug released KPF in the mouse brain in sufficient and effective amounts measured as reduced PGE2 levels. MDPI 2020-04-11 /pmc/articles/PMC7238114/ /pubmed/32290494 http://dx.doi.org/10.3390/pharmaceutics12040344 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Montaser, Ahmed
Lehtonen, Marko
Gynther, Mikko
Huttunen, Kristiina M.
L-Type Amino Acid Transporter 1-Utilizing Prodrugs of Ketoprofen Can Efficiently Reduce Brain Prostaglandin Levels
title L-Type Amino Acid Transporter 1-Utilizing Prodrugs of Ketoprofen Can Efficiently Reduce Brain Prostaglandin Levels
title_full L-Type Amino Acid Transporter 1-Utilizing Prodrugs of Ketoprofen Can Efficiently Reduce Brain Prostaglandin Levels
title_fullStr L-Type Amino Acid Transporter 1-Utilizing Prodrugs of Ketoprofen Can Efficiently Reduce Brain Prostaglandin Levels
title_full_unstemmed L-Type Amino Acid Transporter 1-Utilizing Prodrugs of Ketoprofen Can Efficiently Reduce Brain Prostaglandin Levels
title_short L-Type Amino Acid Transporter 1-Utilizing Prodrugs of Ketoprofen Can Efficiently Reduce Brain Prostaglandin Levels
title_sort l-type amino acid transporter 1-utilizing prodrugs of ketoprofen can efficiently reduce brain prostaglandin levels
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238114/
https://www.ncbi.nlm.nih.gov/pubmed/32290494
http://dx.doi.org/10.3390/pharmaceutics12040344
work_keys_str_mv AT montaserahmed ltypeaminoacidtransporter1utilizingprodrugsofketoprofencanefficientlyreducebrainprostaglandinlevels
AT lehtonenmarko ltypeaminoacidtransporter1utilizingprodrugsofketoprofencanefficientlyreducebrainprostaglandinlevels
AT gynthermikko ltypeaminoacidtransporter1utilizingprodrugsofketoprofencanefficientlyreducebrainprostaglandinlevels
AT huttunenkristiinam ltypeaminoacidtransporter1utilizingprodrugsofketoprofencanefficientlyreducebrainprostaglandinlevels